转移性黑色素瘤患者中罕见的免疫诱导角化棘皮瘤在18F-FDG PET/CT上显示
一例76岁男性IV期晚期黑色素瘤患者接受纳武利尤单抗-伊匹木单抗治疗,并发促肾上腺皮质激素缺乏、甲状腺功能减退和皮疹。首次评估时18F-FDG PET/CT显示完全代谢缓解,允许继续纳武利尤单抗单药治疗;6个月时PET/CT确认完全代谢缓解持续,但显示双大腿外侧皮肤局灶性摄取和下肢皮肤弥漫性摄取。临床表现为严重疣状苔藓样疹伴发疹性角化棘皮瘤,切除后确诊。本文报告一例罕见的免疫治疗诱导角化棘皮瘤,首次由18F-FDG PET/CT显示。
要点
- IV期黑色素瘤患者经纳武利尤单抗-伊匹木单抗治疗后PET/CT显示完全代谢缓解。
- 6个月时PET/CT确认完全代谢缓解持续,但出现双大腿外侧皮肤局灶性摄取和下肢皮肤弥漫性摄取。
- 临床表现为严重疣状苔藓样疹伴发疹性角化棘皮瘤,切除后确诊为免疫治疗诱导角化棘皮瘤。
核心结论
- 本文报告一例罕见的免疫治疗诱导角化棘皮瘤,首次由18F-FDG PET/CT显示。
研究设计与样本
- 病例报告:一例76岁男性IV期晚期黑色素瘤患者,接受纳武利尤单抗-伊匹木单抗治疗。
主要发现
- 首次评估时18F-FDG PET/CT清晰显示完全代谢缓解,允许继续纳武利尤单抗单药治疗。
- 6个月时18F-FDG PET/CT完全确认完全代谢缓解持续,但显示双大腿外侧皮肤局灶性摄取和下肢皮肤弥漫性摄取。
- 临床表现为严重疣状苔藓样疹伴发疹性角化棘皮瘤,切除后确诊。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 76-year-old man managed for stage IV advanced melanoma was treated with nivolumab-ipilimumab, complicated by corticotropic insufficiency, hypothyroidism, and rash. At first evaluation, 18F-FDG PET/CT clearly showed complete metabolic response allowing continued treatment with nivolumab alone. At 6 months, 18F-FDG PET/CT fully confirmed the persistence of complete metabolic response but showed the appearance of cutaneous focal uptakes of both lateral thighs and a cutaneous diffuse uptake on lower limbs. Clinically, he had a severe verrucous lichenoid eruption with eruptive keratoacanthomas, confirmed after resection. We report a case of rare immunotherapy-induced keratoacanthomas first showed by 18F-FDG PET/CT.
引用
- Oillarburu N, Pages C, Sibaud V, et al. Rare Immuno-Induced Keratoacanthomas Showed on 18F-FDG PET/CT in a Metastatic Melanoma Patient. Clin Nucl Med. 2025. PMID: 40179300. doi:10.1097/RLU.0000000000005692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。